ATLANTA, March 20 /PRNewswire-FirstCall/ -- Inhibitex, Inc. announced today that it will present at the BioCentury and Thomson Financial Future Leaders in the Biotech Industry Conference on Thursday, March 30, 2006 at 3:30 p.m. EST from the Millennium Broadway Hotel in New York City. William D. Johnston, Ph.D., president and chief executive officer of Inhibitex, will provide a company and clinical development update.
A live audio webcast of the presentation will be available on the "Investors" section of the Company's website at www.inhibitex.com. The webcast will be archived and available on the Inhibitex website after the event for a period of 30 days.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. The Company currently has six drug development programs, all of which are based on its proprietary MSCRAMM protein platform technology. The Company's most advanced product candidates are Veronate and Aurexis, for which the Company has retained all worldwide rights. Both Veronate and Aurexis have been granted Fast Track designation by the FDA. The Company's preclinical programs include a collaboration and joint development agreement with Dyax Corp. to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines.
For additional information about the Company, please visit www.inhibitex.com.
Inhibitex(R), MSCRAMM(R), Veronate(R) and Aurexis(R) are registered trademarks of Inhibitex, Inc.
CONTACTS: Inhibitex, Inc. Russell H. Plumb Chief Financial Officer (678) 746-1136 rplumb@inhibitex.com Lilian Stern (Investors) Stern Investor Relations, Inc. (212) 362-1200 lilian@sternir.com Kathryn Morris (Media) KMorrisPR (845) 635-9828 kathryn@kmorrispr.com
Inhibitex, Inc.CONTACT: Russell H. Plumb, Chief Financial Officer of Inhibitex, Inc.,+1-678-746-1136, or rplumb@inhibitex.com; or Investors, Lilian Stern ofStern Investor Relations, Inc., +1-212-362-1200, or lilian@sternir.com; orMedia, Kathryn Morris of KMorrisPR, +1-845-635-9828, orkathryn@kmorrispr.com
Web site: http://www.inhibitex.com//
